DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $14 at Lake Street Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
March 14, 2022 4:45 PM EDTConference Call and Webcast March 15 at 8:00 am Eastern Time / 7:00 am Central Time
Currently Dosing Patients in Pivotal Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial Team Expanded with Addition of Chief Medical Officer and Chief Commercial Officer Strong Balance Sheet with $45M Cash, Runway Into 2024MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial... More
